|
|
T1D Podcast
|
Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp |
|
|
|
|
Written by Scott Herring
|
|
Sunday, 25 July 2010 13:48 |
ORLANDO, Fla., June 30 /PRNewswire/ -- Novo Nordisk and Indy Lights race car driver Charlie Kimball announced the availability of "Camp in a Kit", a wide array of resources to help kids with diabetes have a positive and rewarding summer camp experience. The Kits, which come as a backpack filled with camp essentials such as a sleeping bag, fan, flashlight and a calculator, will be available to order from select physicians' offices* for free to kids attending diabetes camps nationwide. They are just one of the programs Novo Nordisk is offering to help campers and parents feel better prepared for their time at summer camp, which for many is also the first time kids will manage their diabetes independently. "Because camp is such an important step toward independence, Novo Nordisk has made supporting diabetes camps, campers and their families a priority by providing grants, resources and employee volunteer time with the goal of making camp a positive and rewarding experience for children and their families." There are more than 185 diabetes camps across North America and each year more than 3,000 children attend.(i) |
|
Read more...
|
|
Smash your computer and help support diabetes |
|
|
|
|
Written by Scott Herring
|
|
Sunday, 25 July 2010 13:37 |
|
Unique event in support of the Canadian Diabetes Association Recently in Canada, there was an event called Smash for a Cure™ to help raise funds in support of the Canadian Diabetes Association’s Camp Jean Nelson. This unique fundraiser allowed you to support leading-edge diabetes research with a ‘pay per hit’ suggested donation. Smash for a Cure™ is part of the Diabetes Summer Surge campaign which gives people an opportunity to take action in their community by hosting a fundraising event (real or virtual), supporting an existing event or making a personal donation all while spreading the word to friends and family. Organizers of the event worked with The Electronics Recycling Association to recycle all the destroyed devices from the event. For more information, visit diabetessummersurge.ca |
|
|
Team Type 1 Takes 1st in Race Across America 8-Person Category |
|
|
|
|
Written by Scott Herring
|
|
Sunday, 25 July 2010 13:35 |
On June 18, 2010, Team Type 1 claimed its third Race Across America 8-person team victory with a total time of five days, ten hours and 48 minutes over the 3,005-mile course from Oceanside, California, to Annapolis, Maryland. Team Type 1 has now claimed victory in the epic, 24-hour-a-day Race Across America three times in 2007, 2009, and now in 2010. Since 2006, a total of 27 athletes with type 1 diabetes have raced 15,125 miles over 27 days, 7 hours and 18 minutes in Race Across America on behalf of Team Type 1 and the millions of people impacted by diabetes around the world. The 2010 Race Across America was filled with ups and downs for Team Type 1, from car accidents and armadillos to erratic blood sugar levels. To make make the 3,005 miles go by easier, the teams were divided into two sub-teams of four riders. Team Type 1 agreed to call themselves “Team Shake” and “Team Bake.” Each team would take a four-hour turn racing while the other team rested. Each member of each team would take pulls of approximately 15 minutes at maximum effort. The sub-teams would rotate for four hours and then switch out with the other team. |
|
Read more...
|
|
Type 1 diabetes vaccine passes Phase 1 clinical trial |
|
|
|
|
Written by Scott Herring
|
|
Sunday, 25 July 2010 13:31 |
|
Bacillus Calmette-Guerin, a vaccine that could reverse Type 1 diabetes, has passed a Phase 1 clinical trial. The first clinical trials for Bacillus Calmette-Guerin show that it may reverse Type 1 diabetes. The Phase 1 clinical trial revealed the vaccine to be safe and effective. A Phase II trial is currently being planned by scientists from Massachusetts General Hospital and the Iacocca Foundation. The Bacillus Calmette-Guerin vaccine works by temporarily raising the levels of tumor necrosis factor in humans and mice. These increased levels eliminate abnormal white cells in individuals with Type 1 diabetes, which causes a reversal of the disease.
|
|
Tolera Therapeutics Granted Orphan Drug Designation |
|
|
|
|
Written by Scott Herring
|
|
Friday, 02 July 2010 20:16 |
KALAMAZOO, Mich., June 22 /PRNewswire/ -- Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes. "We are pleased with this designation," commented John J. Puisis, President and CEO of Tolera. "Clinicians and patients need an effective and safe means to modulate the immune system, particularly for juvenile diabetes patients. Current treatments and industry pipelines offer very few solutions to advance patient care, leaving these young patients with a deteriorating disease condition. Thus far, these treatments can only offset disease symptoms, or slow disease progression, but at the cost of potentially serious side effects. We believe we are developing a therapy that will prove to be both safe and effective, thus providing the patient with a much better treatment outcome." |
|
Read more...
|
|
Entelos Announces Publication of Its Type 1 Diabetes PhysioLab® Platform |
|
|
|
|
Written by Scott Herring
|
|
Monday, 28 June 2010 00:45 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies. Access to a version of the T1D PhysioLab platform is provided by Clinical and Experimental Immunology through supplemental information described in the journal, allowing readers to navigate through the platform to learn about its features and capabilities. To view the abstract, click here. |
|
Read more...
|
|
|
Researchers Discover How Insulin-Producing Cells Increase during Pregnancy |
|
|
|
|
Written by Scott Herring
|
|
Sunday, 25 July 2010 13:32 |
NEW YORK, June 27, 2010 - Researchers funded by JDRF have discovered that the hormone, serotonin, may be involved in the increase of insulin-producing beta cells during pregnancy. The findings reveal one of the mechanisms underlying beta cell expansion during pregnancy, and are the latest advances underscoring the potential for regeneration as a key component of a possible cure for type 1 diabetes. The study, published online today in the journal Nature Medicine, was conducted by a team of researchers at the University of California San Francisco. Studying the gene expression and signaling pathways that regulate the increase of functional beta cells in pregnant mice, the researchers identified that a gene (tryptophan hydroxylase-1 or Tph1) involved in the production of serotonin is dramatically increased in beta cells of the mother during pregnancy. Serotonin is a hormone well known for its various roles in moderating behavior in animals and humans. |
|
Read more...
|
|
Diamyd Medical signs agreement with Ortho-McNeil-Janssen Pharmaceuticals for diabetes therapy |
|
|
|
|
Written by Scott Herring
|
|
Sunday, 25 July 2010 13:28 |
|
Diamyd Medical AB has signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to develop and commercialize the Diamyd(R) diabetes therapy. The agreement relates to the development and world-wide commercialization of the GAD65 antigen-based therapy (Diamyd(R)) for the treatment and prevention of type 1 diabetes and associated conditions. |
|
Last Updated ( Sunday, 25 July 2010 13:30 )
|
|
Read more...
|
|
J&J cuts 2 deals for diabetes treatment |
|
|
|
|
Written by Scott Herring
|
|
Friday, 02 July 2010 20:14 |
|
TRENTON, N.J. — Johnson & Johnson is grabbing for a share of the huge, fast-growing market for diabetes drugs, announcing a pair of partnerships Tuesday that could produce novel medicines for the disease. They would complement a very successful line of blood sugar testing and control equipment. The agreements, with companies in Sweden and California, to develop new drugs for Type 1 and Type 2 diabetes come just days before J&J is to release results of mid-stage human tests of another promising drug, called canagliflozin, likely to be its first diabetes medicine. |
|
Last Updated ( Sunday, 25 July 2010 14:27 )
|
|
Read more...
|
|
The Iacocca Family Foundation and Kineta Announce New Partnership |
|
|
|
|
Written by Scott Herring
|
|
Monday, 28 June 2010 00:37 |
|
The Iacocca Family Foundation and Kineta Announce New Partnership on Type 1 Diabetes Mellitus Drug Development Program Foundation Makes Initial Investment in Kineta’s Lead Autoimmune Drug Candidate with Cutting-Edge Applications Aimed at Ending Insulin Dependence SEATTLE--(BUSINESS WIRE)--Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta’s preclinical autoimmune drug candidate – ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus. “The Iacocca Family Foundation is deeply impressed with the high caliber science imbued in Kineta’s program. We also see tremendous vision to chart a course that may one day eliminate insulin dependence for patients” “The Iacocca Family Foundation is deeply impressed with the high caliber science imbued in Kineta’s program. We also see tremendous vision to chart a course that may one day eliminate insulin dependence for patients,” said Kathryn Iacocca Hentz, President of the Iacocca Family Foundation. |
|
Read more...
|
|
|
|
|
<< Start < Prev 1 2 3 4 Next > End >>
|
|
Page 1 of 4 |
|
|